Organon and Co — Biomedical Watch V2

Traitements6programmes

Essais3liés

Publications0liées

SourceDBlocale

Traitements

6

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Comparator: SumatriptanA study to provide evidence supporting the benefit of Rizatriptan in patients who have an inadequate response to sumatriptan.	Migraine	Phase 3	À vérifier		À vérifier
Comparator: theophylline ER/Duration of Treatment: 16 weeksSubjects have 8-week with montelukast sodium or comparator drug administration period, 2-week wash-out period and 8-week comparator drug or the drug administration period (with cross-over design) for assessment of the drug efficacy, safety and tolerability.	SEP	Phase 4	À vérifier		À vérifier
MK0476; montelukast sodium/Duration of Treatment: 16 weeksSubjects have 8-week with montelukast sodium or comparator drug administration period, 2-week wash-out period and 8-week comparator drug or the drug administration period (with cross-over design) for assessment of the drug efficacy, safety and tolerability.	SEP	Phase 4	À vérifier		À vérifier
rizatriptanA study to provide evidence supporting the benefit of Rizatriptan in patients who have an inadequate response to sumatriptan.	Migraine	Phase 3	À vérifier		À vérifier
rizatriptanA study to provide evidence supporting the benefit of Rizatriptan in patients who have an inadequate response to sumatriptan.	Migraine	Phase 3	À vérifier		À vérifier
MK0476; montelukast sodium/Duration of Treatment: 16 weeksSubjects have 8-week with montelukast sodium or comparator drug administration period, 2-week wash-out period and 8-week comparator drug or the drug administration period (with cross-over design) for assessment of the drug efficacy, safety and tolerability.	SEP	Phase 4	À vérifier		À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
MK0476; montelukast sodium/Duration of Treatment: 16 weeks	SEP	Phase 4	NCT00157937	A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)	COMPLETED
rizatriptan benzoate	Migraine	Phase 3	NCT01004263	A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)	COMPLETED
rizatriptan	Migraine	Phase 3	NCT00894556	A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.